Lucisot (Sotorasib) 120 mg
Lucisot (Sotorasib 120 mg) is a breakthrough medication, known as the first-ever therapy to target the KRAS mutation.
Manufacturer: Lucius Pharmaceuticals. A generic equivalent of Lumakras.
Breaking the "Undruggable" Target:
For decades, the KRAS protein was considered impossible to target with drugs. Lucisot changes everything. It specifically binds to the KRAS G12C mutant protein, locking it in an inactive state and stopping tumor growth signals.
✅ Key Benefit: Offers new hope for patients with the specific KRAS G12C mutation who have progressed after chemotherapy.
Indicated for the treatment of adult patients with KRAS G12C-mutated Non-Small Cell Lung Cancer (NSCLC) who have received at least one prior systemic therapy.
⚠️ Requirement: Presence of KRAS G12C mutation must be confirmed by an FDA-approved test.
Standard Dosage: 960 mg once daily.
⚠️ PILL COUNT AWARENESS:
- Take 8 tablets (120 mg each) once daily at the same time.
- One bottle (56 tabs) lasts exactly 7 days.
💊 Administration:
- Swallow tablets whole. Do not chew, crush, or split.
- Can be taken with or without food.
- Avoid Proton Pump Inhibitors (PPIs) and H2 blockers (antacids), as they reduce the drug's absorption.
- Hypersensitivity to Sotorasib.
- Pregnancy and breastfeeding (potential harm to fetus).
- Severe hepatic impairment.
Common side effects requiring monitoring:
- Hepatotoxicity: Elevated liver enzymes (ALT/AST). Frequent blood tests are necessary.
- Gastrointestinal: Diarrhea, nausea.
- Musculoskeletal pain: Joint or muscle aches.
- Lungs: Cough or dyspnea (monitor for Interstitial Lung Disease).
Similar products
What Customers Say
No reviews yet
Your review can be the first!